Font Size :



Healthcare Business: Healthcare

Business Overview

Pharmaceutical Plant No. 3

Nissan Chemical Corporation entered into the pharmaceutical business in 1982 and launched an external preparation of ketoprofen (brand name: EPATEC®*) in 1985 on the Japanese market. In 1994, a calcium channel blocker efonidipine hydrochloride (brand name: LANDEL®*) was launched as our company’s first new pharmacological for the indication of hypertension. Renoparenchymal hypertension and angina pectoris were added into its indications in 1998. It is also available in South Korea from 2003 under the brand name of “FINTE®.” Moreover, EPATEC® and LANDEL® were succeeded to Zeria Pharmaceutical Co., Ltd in 2008 and 2011, respectively.

Furthermore, Nissan Chemical discovered a new drug, pitavastatin calcium (brand name: LIVALO®*), which has a strong LDL cholesterol reduction effect and launched by Kowa Company, Limited in 2003 on the Japanese market. Currently, it is sold in 30 countries around the world and is also under the process of launching in other countries and territories, as well as the development of compound drugs.

Concerning the new drug development pipeline, a pharmacological treatment for arrhythmia (NTC-801) is under the process of development. The former R&D section for pharmaceuticals was integrated to the Planning and Development Division from April 2022, making the Healthcare Division to handle manufacturing and sales of new drugs, medical materials, etc. From here on, the Healthcare Division will be committed to healthcare business from a broader, holistic viewpoint, not just focusing on pharmaceuticals but also medical materials.


*EPATEC® and LANDEL® are registered trademarks of Zeria Pharmaceutical Co., Ltd. and LIVALO® is a registered trademark of Kowa Company, Limited.

Click here for details of drug discovery research and healthcare R&D

Main Products

Pitavastatin calcium
(brand name: LIVALO®)
This is an antihypercholesterolemic agent characteristic of having a strong LDL cholesterol reduction effect and causing less drug-interactions. It is recognized as one of the “Strong statins” in clinical practice. In Japan, it is distributed by Kowa Company, Limited. It has been launched in 30 countries, such as the United States and countries in Latin America, Europe and Asia. It is also under the process of launching in other countries as well as the development of compound drugs.
Efonidipine hydrochloride
(brand name: LANDEL®, FINTE®)
This is a long-acting calcium channel blocker characteristic of having renal protective functions. It is used for treating hypertension and angina. It is distributed by Zeria Pharmaceutical Co., Ltd. and Shionogi & Co., Ltd. in Japan, and by GC Biopharma Corp. in South Korea.

New Medicines under Development

NTC-801 (pharmacological treatment for arrhythmia)
It is a therapeutic agent which selectively inhibits acetylcholine-sensitive muscarinic potassium channels (KACh) and may be administered orally. KACh is known to be expressed only in the atrium, not in the ventricle. Since it will not interfere with the functions of the ventricles, NTC-801 has the potential to be a flawless treatment option for arrhythmia.

Contact Us

Handling division

  • Healthcare Division, Healthcare Products Sales
  • Contuct Us

Contact Us



Smartphone version is here

We use cookies to help improve your experience on our website.
Clink on "Agree" to agree and proceed, or click on "Data Protection / Privacy Policy" for more information and settings of cookies.
By continuing to use our website, you are deemed to have consented to the use of cookies.